Skip to main content
. Author manuscript; available in PMC: 2023 Jan 25.
Published in final edited form as: Nat Med. 2022 Apr 11;28(5):1022–1030. doi: 10.1038/s41591-022-01762-x

Fig. 5 ∣. Longitudinal neutralization data and the effect of VRC07 paratope binding by 5C9 on neutralization by purified IgG from study participants.

Fig. 5 ∣

a, Neutralization of five different tier 2 pseudoviruses as shown in the figure legend by purified IgG for the first seven trial participant enrolled in VRC 603. Participants A–C received 5 × 1010 vg kg−1; Participants D and E received 5 × 1011 vg kg−1; and Participants F and G received 2.5 × 1012 vg kg−1 of AAV8-VRC07 by IM injection. Longitudinal IgG IC50s are reported as μg ml−1 of purified IgG on the left y axis for each pseudoviral strain. VRC07 concentration as determined by 5C9 titration is reported as ng ml−1 of 1 mg ml−1 of purified IgG on the right y axis. Data points represent single determinations. Data points in the shaded area are below the limits of accurate quantitation. b, Neutralization curves adjusted for the concentration of VRC07 in purified IgG serum samples are shown for Participant C at 0, 6, 12, 24 and 52 weeks after IM injection of AAV8-VRC07, as indicated in the figure legend. Neutralization curves for purified in vitro produced VRC07 for each pseudoviral species are overlaid on each plot. Data points for neutralization assays of ex vivo produced VRC07 represent the average of six replicate assays; error bars are ± s.d. Data points for in vitro produced VRC07 represent a single assay, These data are representative of data for Participants A, B and D–G. c, Representative neutralization curve showing the failure of in vitro produced VRC07 to neutralize pseudoviral strain CAP210.E8.SG3 at weeks 6,12, 28 and 52. Each data point represents a single determination. d, From left to right, neutralization of TZBD by purified IgG from Participant C containing the amount of VRC07 indicated on the x axis from week 28 purified IgG; neutralization of TZBD by purified in vitro produced VRC07; and neutralization of TZBD by in vitro produced VRC13, in the presence or absence of 10 μg ml−1 of the VRC07 paratope-binding monoclonal antibody 5C9, as shown in the figure legend. These data are representative of neutralization curves for Participants A, B and D–G. Each data point represents a single determination.